미세캡슐 (microencapsulation)은 내부 물질(core material)의 방출을 제어하기 위하여 여러 천연 및 생분해성 물질이 사용된다. 유청단백질은 이러한 목적에 아주 적합한 것으로 여겨지고 있는데 이는 독특한 이화학적 특성에 기인되는 것이다. 본 연구팀은 drug이나 생리활성물질을 피복하기 위하여 cross-linking 물질로 glutaraldehyde를 사용하여 수용성 이면서 유청단백질을 근간으로 하는 미세캡슐 제조기술을 개발하였다. 또한 생리적 조건에서 이들 캡슐의 분해 및 포집물질의 방출에 대한 연구를 수행하였는데 수용성 drug으로 사용된 theophylline은 유청단백질에 잘 분산되는 것으로 확인되었다. 이 분산액은 !%의 생리활성물질인 polyurethane을 함유하는 dichloromethane과 hexane 혼합불에 잘 확산이 되었다. 미세캡슐공정에서 피복물질로 사용되는 여러 물질중에서 유청단백질은 생리적 효능이 뛰어나고 여러 물리적 작용이 있기 때문에 새로운 피복소재로써 그 효용성이 매우 높다. 지금까지의 연구결과 유청단백질을 이용한 미세캡슐의 제조는 유청단백질이 가지는 기능적 효과와 내부물질이 지니는 약리효과를 동시에 이용할 수 있다는 점에서 향후 고부가 식품 의약품 첨가물질로써 유용성이 기대된다고 하겠다.
미세캡슐 (microencapsulation)은 내부 물질(core material)의 방출을 제어하기 위하여 여러 천연 및 생분해성 물질이 사용된다. 유청단백질은 이러한 목적에 아주 적합한 것으로 여겨지고 있는데 이는 독특한 이화학적 특성에 기인되는 것이다. 본 연구팀은 drug이나 생리활성물질을 피복하기 위하여 cross-linking 물질로 glutaraldehyde를 사용하여 수용성 이면서 유청단백질을 근간으로 하는 미세캡슐 제조기술을 개발하였다. 또한 생리적 조건에서 이들 캡슐의 분해 및 포집물질의 방출에 대한 연구를 수행하였는데 수용성 drug으로 사용된 theophylline은 유청단백질에 잘 분산되는 것으로 확인되었다. 이 분산액은 !%의 생리활성물질인 polyurethane을 함유하는 dichloromethane과 hexane 혼합불에 잘 확산이 되었다. 미세캡슐공정에서 피복물질로 사용되는 여러 물질중에서 유청단백질은 생리적 효능이 뛰어나고 여러 물리적 작용이 있기 때문에 새로운 피복소재로써 그 효용성이 매우 높다. 지금까지의 연구결과 유청단백질을 이용한 미세캡슐의 제조는 유청단백질이 가지는 기능적 효과와 내부물질이 지니는 약리효과를 동시에 이용할 수 있다는 점에서 향후 고부가 식품 의약품 첨가물질로써 유용성이 기대된다고 하겠다.
Microcapsules consisting of natural, biodegradable polymers for controlled and/or sustained core release applications are needed. Physicochemical properties of whey proteins suggest that they may be suitable wall materials in developing such microcapsules. The objectives of the research were to deve...
Microcapsules consisting of natural, biodegradable polymers for controlled and/or sustained core release applications are needed. Physicochemical properties of whey proteins suggest that they may be suitable wall materials in developing such microcapsules. The objectives of the research were to develop water-insoluble, whey protein-based microcapsules containing a model water-soluble drug using a chemical cross-linking agent, glutaraldehyde, and to investigate core release from these capsules at simulated physiological conditions. A model water soluble drug, theophylline, was suspended in whey protein isolate (WPI) solution. The suspension was dispersed in a mixture of dichloromethane and hexane containing 1% biomedical polyurethane. Protein matrices were cross-linked with 7.5-30 ml of glutaraldehyde-saturated toluene (GAST) for 1-3 hr. Microcapsules were harvested, washed, dried and analyzed for core retention, microstructure, and core release in enzyme-free simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) at 37$^{\circ}C$, A method consisting of double emulsification and heat gelation was also developed to prepare water-insoluble, whey protein-based microcapsules containing anhydrous milkfat (AMF) as a model apolar core. AMF was emulsified into WPI solution (15-30%, pH 4.5-7.2) at a proportion of 25-50% (w/w, on dry basis). The oil-in-water emulsion was then added and dispersed into corn oil (50 $^{\circ}C$)to form an O/W/O double emulsion and then heated at 85$^{\circ}C$ for 20 min for gelation of whey protein wall matrix. Effects of emulsion composition and pH on core retention, microstructure, and water-solubility of microcapsules were determined. Overall results suggest that whey proteins can be used in developing microcapsules for controlled and sustained core release applications.
Microcapsules consisting of natural, biodegradable polymers for controlled and/or sustained core release applications are needed. Physicochemical properties of whey proteins suggest that they may be suitable wall materials in developing such microcapsules. The objectives of the research were to develop water-insoluble, whey protein-based microcapsules containing a model water-soluble drug using a chemical cross-linking agent, glutaraldehyde, and to investigate core release from these capsules at simulated physiological conditions. A model water soluble drug, theophylline, was suspended in whey protein isolate (WPI) solution. The suspension was dispersed in a mixture of dichloromethane and hexane containing 1% biomedical polyurethane. Protein matrices were cross-linked with 7.5-30 ml of glutaraldehyde-saturated toluene (GAST) for 1-3 hr. Microcapsules were harvested, washed, dried and analyzed for core retention, microstructure, and core release in enzyme-free simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) at 37$^{\circ}C$, A method consisting of double emulsification and heat gelation was also developed to prepare water-insoluble, whey protein-based microcapsules containing anhydrous milkfat (AMF) as a model apolar core. AMF was emulsified into WPI solution (15-30%, pH 4.5-7.2) at a proportion of 25-50% (w/w, on dry basis). The oil-in-water emulsion was then added and dispersed into corn oil (50 $^{\circ}C$)to form an O/W/O double emulsion and then heated at 85$^{\circ}C$ for 20 min for gelation of whey protein wall matrix. Effects of emulsion composition and pH on core retention, microstructure, and water-solubility of microcapsules were determined. Overall results suggest that whey proteins can be used in developing microcapsules for controlled and sustained core release applications.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.